Overall, the different activities of CDK4 and CDK6 described in human cancer directly link deregulation of G1-S phase transition to the control of DNA damage and DNA Damage Response and the modification of tumor microenvironment, giving a clear molecular explanation of the success of CDK4 and CDK6 inhibitors in the treatment of human cancers. The gene discussed is CDK6; the disease is cancer.